ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OKYO Okyo Pharma Limited

91.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Okyo Pharma Investors - OKYO

Okyo Pharma Investors - OKYO

Share Name Share Symbol Market Stock Type
Okyo Pharma Limited OKYO London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 91.00 00:00:00
Open Price Low Price High Price Close Price Previous Close
91.00 91.00
more quote information »
Industry Sector
MINING

Top Investor Posts

Top Posts
Posted at 04/4/2023 07:08 by babbler
Not a surprise. UK investors don't get OKYO.
Posted at 14/3/2023 12:21 by faraweigh2
Management and investors well placed now for future gains.Funding in place for significant growth.
Posted at 01/9/2022 15:13 by faraweigh2
Long and strong over on NASDAQ.Investors understand the prospect over there.Volumes increasing and with an upward trajectory too.
Posted at 13/12/2021 11:44 by kasspass
It seems this company lacks credibility and lost investors interest . Sp not moving on what appears to be a positive rns. Volume says all.
Posted at 18/9/2020 09:10 by dodobird25
Volsung. You are evidently a committed OKYO investor. I also believe that the company has growth potential, and I intend to hold, through thick and thin, until the share price approaches double the current value, whenever that happens. Only then will I consider my position. My current holding is 200,000 shares @ approx. 11.1p ave.

I have researched the company as fully as I am able, but from my experiences of other companies, I realise that there are investors out there with more detailed informatio than I am able to access. Should you have any information or insights, that you are willing to share, I would appreciate your input. Regards, and best wishes with your investments.
Posted at 17/9/2020 09:46 by dodobird25
Why are you referring to OKYO investors as losers? I gather that building up a holding following extensive research and in anticipation of future mid- or long-term profits is not your preferred trading methodology?

I have taken the opportunity of topping up earlier today, although my two 30,000 purchases @10.37p and 10.34p respectively are displayed as sells. You are welcome to your opinion, but I have every reason to suppose that there are long-term profits to look forward to.

Meanwhile, I await the company's report at the AGM on Sept 25. Regards.
Posted at 06/8/2020 14:06 by spurs90
Jim Mellon has just dumped his entire stake in tiddler Okyo Pharma, which is developing therapies for inflammatory eye diseases and chronic pain management. Below is a link to the announcement that shows he went down from owning just over 4pc to almost 0.


Now, that does seem a strange move by Mellon - a 'billionaire' investor that is said to be friends with Brexit leader Aaron Banks - given Okyo shares have been surging in recent weeks to almost 17p.

Watching...
Posted at 28/7/2020 09:06 by spurs90
OKYO Pharma Limited
("OKYO" or the "Company")

Issue of convertible loan notes to raise £3,500,000

OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it has raised £3,500,000 through the issue of convertible loan notes ("CLNs"). The proceeds of the CLNs will be used for working capital purposes as detailed below. The CLNs carry an interest rate of 2.15% compounding and have maximum term of 4 years. The CLNs convert into ordinary shares at a price of 8.5p per share. Conversion will be subject to shareholder approval and no conversions may take place prior to 28 February 2021.

The CLNs were placed with a small number of private investors.

OKYO intends to use the net proceeds received from the CLNs, to further the development of its clinical pipeline.

The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.
Posted at 28/3/2019 21:28 by newtothisgame3
!FOLLOWFEED!YOUTUBEVIDEO:nfumP5CKe7c:
The price I expect in #OKYO will sound like a Ramp at these current levels but Im hoping for 5p eventually. It may seem a tall order but I think it will be reached when we get positive news. … …
… …




Standard listing
Okyo joined the standard list section of the London Market in July after a reverse takeover into former miner West African Mining.

The majority shareholder is the Parmetta Group, which holds the original IP for Chemerin.

Picking winners among small biotechs can be difficult for professionals, let alone amateur investors, but the previous successes and track record of management suggest if the compounds are commercial, they will know how to move them forward.

At 2.25p, Okyo is valued at £12mln and is much smaller currently than Tiziana (£139mln) but you would not bet against it following a similar path.





14 March 2019
OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye.

07 March 2019
Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment
Posted at 01/8/2018 12:41 by zen12
See rns they have £2m in the bank. Also large investors with significant holdings. So what you’re saying is totally incorrect.

Your Recent History

Delayed Upgrade Clock